ArticleFrontiers in pharmacology2025
Study on the correlation between plasma concentration of voriconazole and clinical efficacy and safety in elderly patients.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incorporating the metabolic ratio (C-Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the relationship between voriconazole plasma concentration, clinical efficacy, and adverse reactions in elderly patients. Methods: A retrospective analysis was conducted on the clinical data of 37 elderly patients with invasive fungal infections who received voriconazole therapy and underwent therapeutic drug monitoring. The associations between voriconazole plasma concentration, treatment efficacy, and safety were evaluated. Results: After voriconazole treatment, the levels of liver function markers (ALT, AST, GGT, TBIL) significantly increased, while levels of albumin, WBC, neutrophils (NEUT), CRP, and PCT significantly decreased in elderly patients. Voriconazole plasma concentration was negatively correlated with albumin, calcium, and WBC, and positively correlated with ALT, AST, CRP, and PCT (P < 0.05). Multivariate analysis identified glucocorticoid use as an independent factor influencing voriconazole concentration (P < 0.05). No significant association was found between voriconazole concentration and dosage or clinical efficacy (P > 0.05), but a significant correlation was observed with the incidence of hepatotoxicity (P = 0.042), with an optimal predictive threshold of 4.5 μg/mL (AUC = 0.858). Conclusion: Voriconazole plasma concentrations in elderly patients vary widely, and concentrations exceeding 4.5 μg/mL do not enhance efficacy but are associated with an increased risk of hepatotoxicity, warranting close monitoring in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.